Iberiabank Corp Boosts Holdings in Becton Dickinson and Co (BDX)

Iberiabank Corp boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 44.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,051 shares of the medical instruments supplier’s stock after acquiring an additional 5,881 shares during the period. Iberiabank Corp’s holdings in Becton Dickinson and were worth $4,293,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. IMS Capital Management acquired a new position in Becton Dickinson and during the 3rd quarter worth $29,000. JCIC Asset Management Inc. acquired a new position in Becton Dickinson and during the 4th quarter worth $54,000. Acropolis Investment Management LLC acquired a new position in shares of Becton Dickinson and in the 3rd quarter valued at $101,000. Truvestments Capital LLC acquired a new position in shares of Becton Dickinson and in the 3rd quarter valued at $105,000. Finally, Tributary Capital Management LLC acquired a new position in shares of Becton Dickinson and in the 4th quarter valued at $103,000. Hedge funds and other institutional investors own 86.28% of the company’s stock.

In related news, EVP James W. Borzi sold 5,887 shares of the firm’s stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $252.37, for a total value of $1,485,702.19. Following the completion of the sale, the executive vice president now directly owns 6,013 shares in the company, valued at approximately $1,517,500.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of the firm’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $245.83, for a total transaction of $511,326.40. Following the completion of the sale, the senior vice president now owns 4,497 shares of the company’s stock, valued at $1,105,497.51. The disclosure for this sale can be found here. Insiders sold a total of 13,210 shares of company stock valued at $3,275,587 in the last 90 days. 0.12% of the stock is owned by corporate insiders.

BDX has been the topic of a number of analyst reports. TheStreet downgraded Becton Dickinson and from a “b+” rating to a “c+” rating in a research note on Friday, December 7th. KeyCorp increased their price target on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research note on Thursday, November 8th. Citigroup cut their price target on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating on the stock in a research note on Wednesday, January 2nd. Wells Fargo & Co lowered their price objective on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, November 7th. Finally, UBS Group began coverage on shares of Becton Dickinson and in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 price objective for the company. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $253.17.

BDX stock opened at $245.05 on Thursday. The stock has a market cap of $65.45 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 1.70 and a beta of 1.23. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.12. The company had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. Becton Dickinson and’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.48 EPS. As a group, sell-side analysts forecast that Becton Dickinson and Co will post 12.1 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s payout ratio is 27.97%.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/02/14/becton-dickinson-and-co-bdx-position-increased-by-iberiabank-corp.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: What is cost of equity?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply